logo-loader
viewVolitionRx

VolitionRx well funded as it advances development of its novel cancer tests

VolitionRx Limited (NYSEAmerican:VNRX) CEO Cameron Reynolds brings Proactive's Andrew Scott up to date on developments with their cancer blood tests as well as discussing the group's 2018 results.

As of the end of December, Volition's cash position stood at $13.4 million - up from $10.1 million at the close of 2017.

Reynolds says continued development of their Nu.Q Capture and Nu.Q Vet products coupled with the strengthening of the company's product pipeline beyond colorectal cancer will help them generate early revenue.

Quick facts: VolitionRx

Price: 4.48 USD

NYSEMKT:VNRX
Market: NYSEMKT
Market Cap: $184.09 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of VolitionRx named herein, including the promotion by the Company of VolitionRx in any Content on the Site, the Company receives from said issuer...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

VolitionRx CEO discusses 'spectacular' results from Nu.Q proof of concept study

VolitionRx Limited's (NYSEAMERICAN:VNRX) Cameron Reynolds discusses with Proactive London's Andrew Scott the results from the latest proof of concept study on its Nu.Q cancer-test assay. He says the finding's have revealed an impressive ability to detect with accuracy non-Hodgkins lymphoma...

1 week, 3 days ago

2 min read